Lenalidomide in multiple myeloma: current experimental and clinical data

Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).

(2017) P. G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).

(2017) M. Mateos et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older.

(2017) A. P. Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)

(2011) S. Mailankody et al.   BLOOD

Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy

(2011) F Cavallo et al.   LEUKEMIA

Associations between multiple myeloma and other malignancies

(2011) Ola Landgren et al.   LEUKEMIA & LYMPHOMA

Mitotic catastrophe: a mechanism for avoiding genomic instability

(2011) Ilio Vitale et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

(2010) P. G. Richardson et al.   BLOOD

Epithelial plasticity, cancer stem cells and bone metastasis formation

(2010) Gabri van der Pluijm   BONE

Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide

(2010) I N M Micallef et al.   BONE MARROW TRANSPLANTATION

Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen

(2010) A Nazha et al.   BONE MARROW TRANSPLANTATION

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study

(2010) Stephen A. Schey et al.   BRITISH JOURNAL OF HAEMATOLOGY

Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone

(2010) Jesús F. San-Miguel et al.   Clinical Lymphoma Myeloma & Leukemia

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

(2010) J.-L. Harousseau et al.   HAEMATOLOGICA

Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients

(2010) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

(2010) S K Kumar et al.   LEUKEMIA

Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma

(2010) A Palumbo et al.   LEUKEMIA

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

(2010) M A Dimopoulos et al.   LEUKEMIA

Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma

(2010) Jens Hasskarl et al.   LEUKEMIA & LYMPHOMA

Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma

(2009) Uday Popat et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

How I treat multiple myeloma in younger patients

(2009) A. K. Stewart et al.   BLOOD

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)

(2009) S. Knop et al.   BLOOD

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

(2009) S. Kumar et al.   BLOOD

Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism

(2009) L. Escoubet-Lozach et al.   CANCER RESEARCH

 3 Integrin Subunit Mediates the Bone-Resorbing Function Exerted by Cultured Myeloma Plasma Cells

(2009) M. Tucci et al.   CANCER RESEARCH

Relapse/Refractory Myeloma Patient: Potential Treatment Guidelines

(2009) Jesús F. San Miguel   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

(2009) Paul G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study

(2009) Ingemar Turesson et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanism of action of lenalidomide in hematological malignancies

(2009) Venumadhav Kotla et al.   Journal of Hematology & Oncology

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

(2009) M A Dimopoulos et al.   LEUKEMIA

Bone-Resorbing Cells in Multiple Myeloma: Osteoclasts, Myeloma Cell Polykaryons, or Both?

(2009) F. Silvestris et al.   ONCOLOGIST

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

(2008) M. Wang et al.   BLOOD

Lenalidomide in the treatment of multiple myeloma: a review

(2008) X. Armoiry et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

(2008) I Breitkreutz et al.   LEUKEMIA